Icoria’s Paradigm Array Labs Unit Secures Three Contracts
News Sep 09, 2005
Icoria, Inc. has announced that its gene expression profiling service unit Paradigm Array Labs has signed three contracts in the current quarter that are expected to generate up to $1.1 million in revenue.
Under the contracts, which are unrelated, Icoria will provide microarray expression services, analysis and reporting to Duke University, the United States Environmental Protection Agency, and an unnamed biotechnology company.
“Paradigm Array Labs’ broad portfolio of gene expression services, the caliber of our work for the NIEHS, and our compliance with GLP guidelines is generating new business wins for Paradigm Array Labs,” said Faye O’Brien, Sr. Business Director of Icoria.
“We have already exceeded 2004 revenues and are aggressively pursuing new business opportunities, including projects related to clinical trials.”
The four-year Duke University contract involves work on multiple organisms for researchers at the Duke University Superfund Basic Research Center and is focused on gaining a better understanding of the mechanism by which environmental toxicants lead to adverse human and environmental effects.
The two-year EPA contract is also related to environmental toxicants and will utilize a custom microarray for zebrafish designed by Icoria and produced by Agilent.
The third contract for the unnamed biotech company is underway and is expected to be completed by the third quarter of 2006.
“Paradigm Array Lab’s outstanding reputation in the toxicogenomics arena is the result of extensive work with the National Institute of Environmental Health Sciences,” said Patrick Hurban, Ph.D., Director of Investigational Genomics.
“We have expanded our product offering over the past year. We are currently performing exciting work coupling laser capture microdissection with microarray technology as well as microRNA analysis utilizing the new MirChip™ technology.”
Previous work by the International Multiple Sclerosis Genetics Consortium (IMSGC) has identified 233 genetic risk variants. However, these only account for about 20% of overall disease risk, with the remaining genetic culprits proving elusive. A new study has tracked down four of these hard-to-find genes.READ MORE